Dexcom has announced that it plans to launch its new continuous glucose monitor (CGM), the G6, in late 2018.

Early data has shown the G6 to be the most accurate device the California-based tech company has released. One study involving 49 participants found the G6 collected 96 per cent of blood glucose readings within 20 mg/dl of the true glucose value.

The G6 will be one of the first products to emerge from Dexcom’s partnership with tech giant Verily (formerly Google Life Sciences).

It will feature a 10-day wear with just one fingerstick calibration per day. In comparison, Dexcom’s G4 and G5 devices both require twice-daily calibration.

Dexcom plans to submit the G6 for US Food and Drug Administration (FDA) approval later this year, with commercialisation the planned for the end of 2018.

For now, human pilot studies will continue with a first-generation device; a second generation device is then due out in 2020.

Dexcom CEO Kevin Sayer, who was speaking at the company’s Q4 earnings call earlier this week, said: “We believe G6 will represent the next major paradigm shift in continuous glucose monitoring performance standards. G6 will allow us to reduce calibrations initially and provide the foundation for our no-calibration technology.”

Dexcom also plans to release an updated version of the G5 transmitter later this year, which will include an improved touchscreen receiver, an Android platform, and extra app features such as integration of insulin data.

Sayer added that Dexcom is working with Verily to produce a tiny dime-sized CGM that will help people with type 1 diabetes and type 2 diabetes.

This machine would not need any calibration, but because the platform is based on G6 sensor technology, it will not be launched until after the G6.